STOCK TITAN

Vera Therapeutics Inc - VERA STOCK NEWS

Welcome to our dedicated news page for Vera Therapeutics (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vera Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vera Therapeutics's position in the market.

Rhea-AI Summary
Vera Therapeutics, Inc. (VERA) will participate in the 44th Annual TD Cowen Health Care Conference. The company's management team will discuss IgAN and hold a Fireside Chat. Investors can access the webcast and a replay of the event on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
conferences
-
Rhea-AI Summary
Vera Therapeutics, Inc. (VERA) will participate in the 6th Annual Guggenheim Biotechnology Conference in New York on February 7th and 8th. The management team will engage in a fireside chat and be available for one-on-one investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
conferences
-
Rhea-AI Summary
Vera Therapeutics, Inc. has successfully closed its underwritten public offering of 9,274,194 shares of its Class A common stock, raising approximately $287.5 million. J.P. Morgan, TD Cowen, and Evercore ISI acted as joint book-running managers for the offering, with LifeSci Capital as the lead manager. The offering was made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the SEC. The press release emphasizes the final prospectus supplement and accompanying prospectus relating to the offering, which are available for free on the SEC’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
offering
Rhea-AI Summary
Vera Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 8,064,517 shares of its Class A common stock at $31.00 per share, expected to generate approximately $250.0 million in gross proceeds. The offering is expected to close on February 1, 2024, and has the potential for additional shares to be purchased by underwriters. The proposed offering is being made pursuant to a shelf registration statement on Form S-3 and a related registration statement on Form S-3MEF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
offering
-
Rhea-AI Summary
Vera Therapeutics, Inc. plans to commence a public offering to issue and sell $200.0 million of shares of its Class A common stock. The underwriters will have a 30-day option to purchase up to an additional 15% of the shares. The proposed offering is being made pursuant to a shelf registration statement on Form S-3. J.P. Morgan, TD Cowen, and Evercore ISI are acting as joint book-running managers for the proposed offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.46%
Tags
offering
-
Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) announced positive 72-week data from the open label extension (OLE) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN), showing consistent and sustained reductions in Gd-lgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment. Participants treated with atacicept for 72 weeks demonstrated a 62% reduction in Gd-IgA1, a reduction in the percentage of participants with hematuria to 19%, and a 48% reduction in UPCR in the per-protocol (PP) analysis. Safety data indicated that atacicept was generally well-tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.71%
Tags
clinical trial
Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) announces the appointment of two industry veterans to lead the development of the company’s drug programs, including its late-stage product candidate, atacicept, currently in a Phase 3 clinical trial for IgA nephropathy (IgAN). Dr. Robert M. Brenner, a respected nephrologist and biotechnology executive, is appointed as Chief Medical Officer, while Mr. William D. Turner, with nearly 30 years of drug development and commercialization experience, is appointed as Chief Development Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.74%
Tags
management
-
Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) to Host R&D Day with Phase 2b Clinical Trial Data Presentation for Atacicept on January 25, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.74%
Tags
conferences clinical trial
-
Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 7 – 11, 2024. The management team will also participate in one-on-one investor meetings. The presentation will be on Tuesday, January 9th at 3:00 PM PST and can be accessed via webcast. A replay of the event will be available for 90 days on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
Rhea-AI Summary
Vera Therapeutics, Inc. (Nasdaq: VERA) reported positive data from the Phase 2b ORIGIN trial at Kidney Week 2023, supporting the potential of atacicept as a treatment for IgA nephropathy (IgAN). The company also presented strong financial results and a robust balance sheet, with upcoming milestones including the presentation of Phase 2b open-label extension data in Q1 2024 and full enrollment of Phase 3 ORIGIN 3 trial in H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
earnings
Vera Therapeutics Inc

Nasdaq:VERA

VERA Rankings

VERA Stock Data

2.23B
31.37M
5.76%
91.46%
11.54%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Brisbane

About VERA

trucode gene repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. the elegance of triplex gene editing lies in its ability to harness natural, high-fidelity dna repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors.